In the present study, we aim to investigate the efficacy and safety of concurrent therapy of Immunotherapy based combination therapy and Radiotherapy in patients with advanced HCC showing macrovascular invasion.
Signed informed consent form
Age >= 19 at the time of signing Informed consent form
Histological or clinical diagnosis of HCC based on the guidelines of the Korean Liver Cancer Association -National Cancer Center
Unresectable and/or locally advanced or metastatic disease showing major vascular invasion
Fibrolamellar carcinoma or sarcomatoid carcinoma
Receipt of 2 or more prior systemic therapy for advanced HCC. Additional prior systemic therapies used as adjuvant or local therapy are allowed.
Receipt of other first-line systemic therapy than immune checkpoint inhibitor-based regimen
Receipt of prior radiation therapy to liver